Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths globally. Sorafenib is the only first-line systemic drug for advanced HCC, but it has very limited survival benefits because patients treated with sorafenib either suffer from side effects or show disease progressio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gene Expr
Autors principals: Reyes, Ryan, Wani, Nissar A., Ghoshal, Kalpana, Jacob, Samson T., Motiwala, Tasneem
Format: Artigo
Idioma:Inglês
Publicat: Cognizant Communication Corporation 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5296238/
https://ncbi.nlm.nih.gov/pubmed/27938509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/105221616X693855
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars